List view / Grid view

News

Abbott completes acquisition of CFR Pharmaceuticals

29 September 2014 | By Abbott

Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets...

Positive Phase 3 data for Opdivo (nivolumab) in advanced melanoma patients previously treated with yervoy (ipilimumab) presented at the ESMO 2014 Congress; first phase 3 results presented for a PD-1 immune checkpoint inhibitor

29 September 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab)...